Division of Nephrology, University of California San Francisco and San Francisco VA Medical Center, CA, USA.
Division of Nephrology, Department of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
J Cachexia Sarcopenia Muscle. 2017 Feb;8(1):57-68. doi: 10.1002/jcsm.12130. Epub 2016 Aug 11.
There is no consensus on how best to define low muscle mass in patients with end-stage renal disease. Use of muscle mass normalized to height-squared has been suggested by geriatric societies but may underestimate sarcopenia, particularly in the setting of excess adiposity. We compared four definitions of low muscle mass in a prevalent hemodialysis cohort.
ACTIVE/ADIPOSE enrolled prevalent patients receiving hemodialysis from the San Francisco and Atlanta areas from June 2009 to August 2011. Whole-body muscle mass was estimated using bioelectrical impedance spectroscopy, performed before a midweek dialysis session (n = 645; age 56.7 ± 14.5 years, 41% women). We defined low muscle mass as muscle mass of 2SD or more below sex-specific bioelectrical impedance spectroscopy-derived means for young adults (18-49 years) from National Health and Nutrition Examination Survey and indexed to height , body weight (percentage), body surface area (BSA) by the DuBois formula, or Quételet's body mass index (BMI). We compared prevalence of low muscle mass among the four methods and assessed their correlation with strength and physical performance.
The prevalence of low muscle mass ranged from 8 to 32%. Muscle mass indexed to height classified the smallest percentage of patients as having low muscle mass, particularly among women, whereas indexing by BSA classified the largest percentage. Low muscle mass/height was present almost exclusively among normal or underweight patients, whereas indexing to body weight and BMI classified more overweight and obese patients as having low muscle mass. Handgrip strength was lower among those with low muscle mass by all methods except height . Handgrip strength was directly and modestly correlated with muscle mass normalized by percentage of body weight, BSA, and BMI (ρ = 0.43, 0.56, and, 0.64, respectively) and less so with muscle/height (ρ = 0.31, P < 0.001). The difference in grip strength among patients with low vs. normal muscle mass was largest according to muscle/BMI (-6.84 kg, 95% CI -8.66 to -5.02, P < 0.001). There were significant direct correlations of gait speed with muscle mass indexed to percentage of body weight, BSA, and BMI but not with muscle mass indexed to height .
Skeletal muscle mass normalized to height may underestimate the prevalence of low muscle mass, particularly among overweight and obese patients on hemodialysis. Valid detection of sarcopenia among obese patients receiving hemodialysis requires adjustment for body size.
目前,对于终末期肾病患者,如何最好地定义低肌肉量尚无共识。老年学会建议使用肌肉量与身高平方的比值来定义,但这可能会低估肌肉减少症,尤其是在存在过多脂肪的情况下。我们在一个普遍的血液透析队列中比较了四种低肌肉量的定义。
ACTIVE/ADIPOSE 研究纳入了 2009 年 6 月至 2011 年 8 月期间来自旧金山和亚特兰大地区的正在接受血液透析的患者。在每周透析期间的中间时间进行全身肌肉量估计(n=645;年龄 56.7±14.5 岁,41%为女性)。我们将低肌肉量定义为肌肉量低于年轻成年人(18-49 岁)的性别特异性生物电阻抗分析衍生平均值的 2 个标准差或更多,该值源自全国健康和营养检查调查,并通过身高、体重(%)、杜波依斯公式的体表面积(BSA)或奎特莱特的体重指数(BMI)进行身高标准化。我们比较了四种方法中低肌肉量的患病率,并评估了它们与力量和身体表现的相关性。
低肌肉量的患病率范围为 8%至 32%。以身高为指标的肌肉量将患者中最小比例归类为低肌肉量,尤其是女性,而以 BSA 为指标的肌肉量则将患者中最大比例归类为低肌肉量。低肌肉量/身高仅存在于正常或体重不足的患者中,而以体重和 BMI 为指标的肌肉量则将更多超重和肥胖患者归类为低肌肉量。除身高外,所有方法的握力都较低。握力与肌肉量以体重的百分比、BSA 和 BMI 进行标准化呈直接和适度相关(ρ=0.43、0.56 和 0.64),而与肌肉/身高的相关性较小(ρ=0.31,P<0.001)。与肌肉量正常的患者相比,根据肌肉量/BMI(-6.84kg,95%CI-8.66 至-5.02,P<0.001),低肌肉量患者的握力差异最大。步态速度与肌肉量以体重的百分比、BSA 和 BMI 进行标准化呈显著直接相关,但与肌肉量以身高标准化无关。
身高标准化的骨骼肌量可能低估了肌肉量减少症的患病率,尤其是在超重和肥胖的血液透析患者中。为了在肥胖的血液透析患者中有效检测肌肉减少症,需要根据体型进行调整。